{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:42:14Z","timestamp":1788176534002,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR\u20102, addresses this knowledge gap and reports on data collected from 240 patients with relapsed\/refractory MCL in Europe who were treated with BTKi\u2010based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6\u2009months (95% confidence interval [CI] 11.6\u201320.0) in the overall cohort, 5.5\u2009months (95% CI 3.9\u20138.2) in 91 patients without post\u2010BTKi therapy, and 23.8\u2009months (95% CI 18.9\u201330.1) in 149 patients who received post\u2010BTKi therapy (excluding chimeric antigen receptor T\u2010cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post\u2010BTKi therapy, with lenalidomide\u2010containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post\u2010BTKi therapy was 9.7\u2009months (95% CI 6.3\u201312.7). These results provide a benchmark for survival in patients with R\/R MCL receiving salvage therapy after BTKi failure.<\/jats:p>","DOI":"10.1111\/bjh.18519","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T02:26:40Z","timestamp":1666146400000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["<scp>Real\u2010world<\/scp> experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR<\/scp>\u20102 retrospective chart review study"],"prefix":"10.1111","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-5688","authenticated-orcid":false,"given":"Georg","family":"Hess","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center University Medical School of the Johannes Gutenberg\u2010University  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, LMU Klinikum  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-1983","authenticated-orcid":false,"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gine","sequence":"additional","affiliation":[{"name":"Department of Hematology, GELTAMO Hospital Cl\u00ednic of Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u2018Ser\u00e0gnoli\u2019, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Linton","sequence":"additional","affiliation":[{"name":"The Manchester Cancer Research Center  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Vilmar","sequence":"additional","affiliation":[{"name":"Odense University Hospital  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology Skane University Hospital and Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-3699","authenticated-orcid":false,"given":"Jenny M. H.","family":"Chen","sequence":"additional","affiliation":[{"name":"PRECISIONheor  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Ohler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center University Medical School of the Johannes Gutenberg\u2010University  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III Ulm University  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Saint\u2010Louis, Hemato\u2010Oncologie Universit\u00e9 de Paris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lambert","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[{"name":"Division of Hematology ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan\u2010Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"GELTAMO, Institut Catal\u00e0 d'Oncologia Hospital Germans Trias i Pujol  Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez\u2010Ubieto","sequence":"additional","affiliation":[{"name":"GELTAMO Hospital Doce de Octubre  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fischer","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, LMU Klinikum  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-1536","authenticated-orcid":false,"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[{"name":"PRECISIONheor  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Park","sequence":"additional","affiliation":[{"name":"PRECISIONheor  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Kite Pharma  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"Kite Pharma  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reitan","sequence":"additional","affiliation":[{"name":"RJM Group, LLC  Crown Point Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Wade","sequence":"additional","affiliation":[{"name":"Wade Outcomes Research and Consulting  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15283"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4345"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0488"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0537-5"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013326"},{"key":"e_1_2_9_8_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology (NCCN guidelines): B\u2010cell lymphomas version 5.2021 \u2014 September 22 2021"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16416"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567"},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency.Tecartus: EPAR\u2014Public assessment reportAvailable from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/tecartus\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_9_14_1","unstructured":"U.S Food & Drug Administration.FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma2020 Available from:https:\/\/www.fda.gov\/drugs\/fda\u2010approves\u2010brexucabtagene\u2010autoleucel\u2010relapsed\u2010or\u2010refractory\u2010mantle\u2010cell\u2010lymphoma."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_9_23_1","unstructured":"HessG DreylingM ObericL GineE ZinzaniPL LintonK et al. editors.KTE\u2010X19 versus standard of care for relapsed\/refractory mantle cell lymphoma previously treated with bruton tyrosine kinase inhibitors: real\u2010world evidence from EuropeEuropean Hematology Association;2021; Presented at EHA 2021 Virtual Congress June 9\u201017 2021."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T02:35:15Z","timestamp":1725849315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/bjh.18519"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18519","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}